Lenvatinib besylate is a targeted cancer therapy, specifically a tyrosine kinase inhibitor, used to treat advanced, metastatic, or progressive cancers, including differentiated thyroid cancer, hepatocellular carcinoma (liver cancer), and renal cell carcinoma (kidney cancer) in combination with pembrolizumab. It also treats advanced endometrial carcinoma. It is grouped under the following drug class(es): Antineoplastic agents, Kinase inhibitors and VEGF inhibitors. The directory classifies it as a unknown/inactive API with a synthetic source/manufacturing origin. Other names for this substance include CV6VKC887R. Its PubChem CID is 176489806.
Lenvatinib besylate
| CAS No | 2414382-25-3 |
|---|---|
| Molecular Formula | C27H25ClN4O7S |
| Molecular Weight | 585.0 g/mol |
| Synonyms | benzenesulfonic acid;4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxyquinoline-6-carboxamide |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Lenvatinib besylate is a targeted cancer therapy, specifically a tyrosine kinase inhibitor, used to treat advanced, metastatic, or progressive cancers, including differentiated thyroid cancer, hepatocellular carcinoma (liver cancer), and renal cell carcinoma (kidney cancer) in combination with pembrolizumab.
The listed CAS number is 2414382-25-3.
The listed molecular formula is C27H25ClN4O7S.
The listed molecular weight is 585.0 g/mol.
benzenesulfonic acid;4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxyquinoline-6-carboxamide.
The source lists CV6VKC887R.